GB9315856D0
(en)
*
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5541231A
(en)
*
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
US5616344A
(en)
*
|
1994-06-14 |
1997-04-01 |
Fuisz Technologies Ltd. |
Apparatus and process for strengthening low density compression dosage units and product therefrom
|
SI1017392T1
(en)
*
|
1997-09-25 |
2002-12-31 |
Bayer Aktiengesellschaft |
Medicament formulation with a controlled release of an active agent
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
JP2002501890A
(ja)
*
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(+)−ビュープロピオンの薬学的使用
|
AU2349999A
(en)
*
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmacological uses of pure (+) -bupropion
|
JP2002501892A
(ja)
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(−)−ビュープロピオンの薬学的使用
|
CA2318738A1
(fr)
*
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Procedes et compositions de (-)-bupropion optiquement pur destines a faciliter la desaccoutumance au tabac et au traitement de douleurs et d'autres troubles
|
US6150420A
(en)
*
|
1998-06-01 |
2000-11-21 |
Theramax, Inc. |
Method for enhanced brain delivery of bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6096341A
(en)
*
|
1998-10-30 |
2000-08-01 |
Pharma Pass Llc |
Delayed release tablet of bupropion hydrochloride
|
US6033686A
(en)
*
|
1998-10-30 |
2000-03-07 |
Pharma Pass Llc |
Controlled release tablet of bupropion hydrochloride
|
US6238697B1
(en)
*
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6210716B1
(en)
*
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
USD430285S
(en)
*
|
1999-04-16 |
2000-08-29 |
Merck & Co., Inc. |
Tablet
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
NZ518739A
(en)
*
|
1999-11-02 |
2004-12-24 |
Depomed Inc |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
CA2796884A1
(fr)
*
|
2001-02-08 |
2002-08-15 |
Andrx Pharmaceuticals, Inc. |
Forme posologique orale a liberation regulee amelioree
|
ITMI20011457A1
(it)
*
|
2001-07-09 |
2003-01-09 |
Valpharma Sa |
Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
EP2316468A1
(fr)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Système de distribution et méthodes de protection et d'administration de dextroamphetamine
|
MXPA04011203A
(es)
|
2002-05-17 |
2005-07-14 |
Univ Duke |
Metodo para tratar la obesidad.
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
CA2501324A1
(fr)
*
|
2002-10-30 |
2004-05-21 |
Pharmacia Corporation |
Comprimes oraux a liberation etendue et procedes de fabrication et d'utilisation associes
|
US20040096497A1
(en)
*
|
2002-11-19 |
2004-05-20 |
Ponder Garratt W. |
Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
EP2316456B1
(fr)
*
|
2003-04-29 |
2017-06-14 |
Orexigen Therapeutics, Inc. |
Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US8075872B2
(en)
*
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
CN1819821B
(zh)
*
|
2003-08-08 |
2010-10-13 |
拜奥维尔实验室国际股份有限公司 |
盐酸安非他酮的改良释放片剂
|
CA2553207A1
(fr)
|
2004-01-13 |
2005-08-04 |
Kishore M. Gadde |
Compositions anticonvulsives, medicament antipsychotique et leurs methodes d'utilisation permettant d'influer sur la perte de poids
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
WO2005107806A1
(fr)
*
|
2004-04-21 |
2005-11-17 |
Orexigen Therapeutics, Inc. |
Compositions agissant sur une perte de poids
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
US8586085B2
(en)
|
2004-11-08 |
2013-11-19 |
Biokey, Inc. |
Methods and formulations for making pharmaceutical compositions containing bupropion
|
GB0425445D0
(en)
*
|
2004-11-18 |
2004-12-22 |
Smithkline Beecham Corp |
Novel compositions
|
KR100670798B1
(ko)
|
2004-12-17 |
2007-01-17 |
한국전자통신연구원 |
데이터베이스 캐시 시스템
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
WO2007002597A2
(fr)
*
|
2005-06-27 |
2007-01-04 |
Biovail Laboratories International S.R.L. |
Formulations a liberation modifiee d'un sel de bupropion
|
AU2006304889A1
(en)
*
|
2005-10-14 |
2007-04-26 |
H. Lundbeck A/S |
Stable pharmaceutical formulations containing escitalopram and bupropion
|
AU2006308635A1
(en)
*
|
2005-10-14 |
2007-05-10 |
H. Lundbeck A/S |
Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
|
WO2007067341A2
(fr)
|
2005-11-22 |
2007-06-14 |
Orexigen Therapeutics, Inc. |
Compositions et procedes d’augmentation de la sensibilite a l’insuline
|
WO2007062228A1
(fr)
*
|
2005-11-28 |
2007-05-31 |
Orexigen Therapeutics, Inc. |
Formulation de zonisamide a liberation prolongee
|
US8372861B2
(en)
*
|
2006-02-27 |
2013-02-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitors of the unfolded protein response and methods for their use
|
WO2007103366A2
(fr)
|
2006-03-07 |
2007-09-13 |
Osteoscreen Ip, Llc |
RENFORCEMENT DE L'OS ET DU CARTILAGE PAR UN INHIBITEUR DE LA HMG Co-A RÉDUCTASE
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
CN101808634A
(zh)
|
2006-06-13 |
2010-08-18 |
利兰·斯坦福青年大学托管委员会 |
半胱氨酸蛋白酶的环氧化物抑制剂
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
WO2008023390A2
(fr)
*
|
2006-08-21 |
2008-02-28 |
Jubilant Organosys Limited |
Composition pharmaceutique de chlorhydrate de bupropion à libération modifiée
|
MX343867B
(es)
|
2006-11-09 |
2016-11-25 |
Orexigen Therapeutics Inc |
Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
|
KR101479324B1
(ko)
|
2006-11-09 |
2015-01-05 |
오렉시젠 세러퓨틱스 인크. |
신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
EP2142183A2
(fr)
|
2007-04-09 |
2010-01-13 |
Sepracor Inc. |
Procédés et compositions destinées au traitement de troubles respiratoires liés au sommeil
|
US20090023744A1
(en)
*
|
2007-06-18 |
2009-01-22 |
The General Hospital Corporation |
Combination therapy for depression
|
US20090162434A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Disphar International Bv |
Mesalazine tablet
|
BRPI0906467C1
(pt)
|
2008-01-25 |
2021-05-25 |
Gruenenthal Gmbh |
forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
|
US9339500B2
(en)
|
2008-03-04 |
2016-05-17 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
LT2273983T
(lt)
|
2008-05-09 |
2016-10-25 |
Grünenthal GmbH |
Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
|
CA2725930A1
(fr)
|
2008-05-30 |
2009-12-30 |
Orexigen Therapeutics, Inc. |
Procedes pour traiter des pathologies des graisses viscerales
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
TW201105316A
(en)
*
|
2009-07-22 |
2011-02-16 |
Gruenenthal Gmbh |
Hot-melt extruded pharmaceutical dosage form
|
KR101747156B1
(ko)
|
2009-07-22 |
2017-06-27 |
그뤼넨탈 게엠베하 |
산화-안정화된 탬퍼-내성 용량형
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US9248123B2
(en)
|
2010-01-11 |
2016-02-02 |
Orexigen Therapeutics, Inc. |
Methods of providing weight loss therapy in patients with major depression
|
CN102821757B
(zh)
|
2010-02-03 |
2016-01-20 |
格吕伦塔尔有限公司 |
通过挤出机制备粉末状药物组合物
|
RU2607499C2
(ru)
|
2010-09-02 |
2017-01-10 |
Грюненталь Гмбх |
Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
|
MX2013002377A
(es)
|
2010-09-02 |
2013-04-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
|
US9085570B2
(en)
|
2010-10-11 |
2015-07-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Substituted benzamides and their uses
|
EP2632927B1
(fr)
|
2010-10-26 |
2016-02-10 |
Mars, Incorporated |
Boronates en tant qu'inhibiteurs d'arginase
|
EA201400173A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
EA201400172A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
SG10201607685SA
(en)
|
2011-11-21 |
2016-11-29 |
Calithera Biosciences Inc |
Heterocyclic inhibitors of glutaminase
|
JP6117249B2
(ja)
|
2012-02-28 |
2017-04-19 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
|
SG11201406518XA
(en)
|
2012-04-12 |
2014-11-27 |
Univ Leland Stanford Junior |
Substituted benzamides and their uses
|
JP6282261B2
(ja)
|
2012-04-18 |
2018-02-21 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
不正使用防止および過量放出防止医薬剤形
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
AU2013271622B2
(en)
|
2012-06-06 |
2018-03-01 |
Nalpropion Pharmaceuticals Llc |
Methods of treating overweight and obesity
|
PL2920168T3
(pl)
|
2012-11-16 |
2022-01-03 |
Calithera Biosciences, Inc. |
Heterocykliczne inhibitory glutaminazy
|
EP4218829A3
(fr)
|
2013-03-15 |
2023-08-16 |
The Board of Trustees of the Leland Stanford Junior University |
Composés de sonde basée sur l'activité, compositions et méthodes d'utilisation
|
AU2014273227B2
(en)
|
2013-05-29 |
2019-08-15 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
AR096439A1
(es)
|
2013-05-29 |
2015-12-30 |
Gruenenthal Gmbh |
Forma de dosificación resistente al uso indebido que contiene una o más partículas
|
CA2917136C
(fr)
|
2013-07-12 |
2022-05-31 |
Grunenthal Gmbh |
Forme posologique inviolable contenant un polymere d'ethylene-acetate de vinyle
|
JP6480936B2
(ja)
|
2013-11-26 |
2019-03-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
クライオミリングによる粉末状医薬組成物の調製
|
AU2015261060A1
(en)
|
2014-05-12 |
2016-11-03 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising Tapentadol
|
EA201692388A1
(ru)
|
2014-05-26 |
2017-05-31 |
Грюненталь Гмбх |
Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
|
JP6798890B2
(ja)
|
2014-06-13 |
2020-12-09 |
キャリセラ バイオサイエンシーズ, インコーポレイテッド |
グルタミナーゼ阻害剤との併用療法
|
WO2016022969A1
(fr)
|
2014-08-07 |
2016-02-11 |
Calithera Biosciences, Inc. |
Formes cristallines d'inhibiteurs de glutaminase
|
EP3180332B1
(fr)
|
2014-08-13 |
2021-10-27 |
Eolas Therapeutics Inc. |
Difluoropyrrolidines en tant que modulateurs des récepteurs de l'orexine
|
EP3212195A4
(fr)
|
2014-10-31 |
2018-06-06 |
The Regents of The University of California |
Compositions et méthodes de traitement d'un dysfonctionnement cognitif associé au vih
|
CN114044760A
(zh)
|
2015-03-10 |
2022-02-15 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
|
MX2017013637A
(es)
|
2015-04-24 |
2018-03-08 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
|
US10143699B2
(en)
|
2015-06-23 |
2018-12-04 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
KR102305932B1
(ko)
*
|
2015-06-29 |
2021-09-28 |
플로로놀 인코퍼레이티드 |
갈조류의 고체 약제학적 조성물
|
CA2998259A1
(fr)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
CA3000996A1
(fr)
|
2015-10-05 |
2017-04-13 |
Calithera Biosciences, Inc. |
Polytherapie a l'aide d'inhibiteurs de glutaminase et agents immuno-oncologiques
|
SG10201911406TA
(en)
|
2015-10-30 |
2020-01-30 |
Calithera Biosciences Inc |
Compositions and methods for inhibiting arginase activity
|
MX2018005872A
(es)
|
2015-11-16 |
2019-05-16 |
Ichorion Therapeutics Inc |
Profarmacos de acido nucleico.
|
KR20180107232A
(ko)
|
2016-02-12 |
2018-10-01 |
아스트라제네카 아베 |
오렉신 수용체 조정제로서의 할로-치환된 피페리딘
|
WO2017210565A1
(fr)
|
2016-06-03 |
2017-12-07 |
Prisident And Fellows Of Harvard College |
Composés antifongiques
|
WO2018039612A1
(fr)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions et méthodes favorisant la croissance des cheveux au moyen d'inhibiteurs de mpc1
|
EP3510040A4
(fr)
|
2016-09-09 |
2020-06-03 |
Calithera Biosciences, Inc. |
Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
|
US10980767B2
(en)
|
2016-09-09 |
2021-04-20 |
The Regents Of The University Of California |
Estrogen receptor ligands, compositions and methods related thereto
|
WO2018058029A1
(fr)
|
2016-09-26 |
2018-03-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de protéine chromobox et leurs utilisations
|
CA3038528A1
(fr)
|
2016-09-28 |
2018-04-05 |
Medicon Pharmaceuticals, Inc. |
Compositions et methodes de traitement de troubles ophtalmologiques
|
HRP20230634T1
(hr)
|
2016-09-28 |
2023-10-13 |
Medicon Pharmaceuticals, Inc. |
Pripravci za liječenje oftalmoloških stanja
|
AU2017356942A1
(en)
|
2016-11-08 |
2019-05-23 |
Calithera Biosciences, Inc. |
Arginase inhibitor combination therapies
|
ES2970715T3
(es)
|
2016-12-22 |
2024-05-30 |
Prec Pharmaceuticals Inc |
Composiciones y métodos para inhibir la actividad de la arginasa
|
AU2017382460A1
(en)
|
2016-12-23 |
2019-05-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Activity-based probe compounds, compositions, and methods of use
|
CN110430880A
(zh)
|
2017-01-18 |
2019-11-08 |
范德比尔特大学 |
作为选择性bmp抑制剂的稠合杂环化合物
|
MX2019010096A
(es)
|
2017-02-24 |
2020-01-09 |
Merck Patent Gmbh |
Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
|
WO2018178947A2
(fr)
|
2017-03-31 |
2018-10-04 |
Aurigene Discovery Technologies Limited |
Composés et compositions pour le traitement de troubles hématologiques
|
WO2018209288A1
(fr)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Complexes d'arn double brin de protéine argonaute et leurs utilisations
|
WO2018223032A1
(fr)
|
2017-06-02 |
2018-12-06 |
Stealth Biotherapeutics Corp. |
Formes cristallines de sel de sbt-20
|
MX2019015475A
(es)
|
2017-06-30 |
2020-02-19 |
Univ California |
Composiciones y metodos para modular el crecimiento del cabello.
|
WO2019018539A1
(fr)
|
2017-07-19 |
2019-01-24 |
California Institute Of Technology |
Procédés de préparation de composés contenant bis-tétrahydroisoquinoline
|
EA202090536A1
(ru)
|
2017-10-11 |
2020-07-22 |
Ориджен Дискавери Текнолоджис Лимитед |
Кристаллические формы 3-замещенного 1,2,4-оксадиазола
|
CN117064897A
(zh)
|
2017-10-31 |
2023-11-17 |
库里斯公司 |
用于治疗血液病的化合物和组合物
|
CN111372584A
(zh)
|
2017-11-03 |
2020-07-03 |
奥瑞基尼探索技术有限公司 |
Tim-3和pd-1途径的双重抑制剂
|
EP3706798A1
(fr)
|
2017-11-06 |
2020-09-16 |
Aurigene Discovery Technologies Limited |
Thérapies conjointes à des fins d'immunomodulation
|
AR113995A1
(es)
|
2017-12-22 |
2020-07-08 |
Medimmune Ltd |
Moduladores de molécula pequeña del domino de btb de keap1
|
US10745400B2
(en)
|
2018-03-14 |
2020-08-18 |
Vanderbuilt University |
Inhibition of BMP signaling, compounds, compositions and uses thereof
|
US10933084B2
(en)
|
2018-04-12 |
2021-03-02 |
MatRx Therapeutics Corporation |
Compositions and methods for treating elastic fiber breakdown
|
WO2019217450A1
(fr)
|
2018-05-08 |
2019-11-14 |
Rhode Island Hospital |
Anticorps anti-chi3l1 pour la détection et/ou le traitement d'une stéatose hépatique non alcoolique / stéatohépatite non alcoolique et des complications subséquentes
|
EP3813841A4
(fr)
|
2018-06-29 |
2022-03-09 |
The Regents Of The University Of California |
Nouvelles pinces moléculaires contre des troubles neurologiques et des infections virales
|
SG11202100429TA
(en)
|
2018-07-27 |
2021-02-25 |
California Inst Of Techn |
Cdk inhibitors and uses thereof
|
AU2019336698A1
(en)
|
2018-09-05 |
2021-03-25 |
Aztherapies, Inc. |
Methods of treating cytokine release syndrome
|
CA3117695A1
(fr)
|
2018-10-26 |
2020-04-30 |
Keros Therapeutics, Inc. |
Formes cristallines d'un inhibiteur d'alk2
|
CN113574055B
(zh)
|
2019-01-18 |
2024-07-23 |
阿斯利康(瑞典)有限公司 |
Pcsk9抑制剂及其使用方法
|
WO2020154656A1
(fr)
|
2019-01-25 |
2020-07-30 |
Brown University |
Compositions et procédés pour traiter, prévenir ou inverser une inflammation et des troubles associés à l'âge
|
WO2020160323A2
(fr)
|
2019-01-31 |
2020-08-06 |
Elektrofi, Inc. |
Formation et morphologie de particules
|
CN113573709A
(zh)
|
2019-03-14 |
2021-10-29 |
阿斯利康(瑞典)有限公司 |
用于体重减轻的兰比斯特
|
CN113874375A
(zh)
|
2019-06-03 |
2021-12-31 |
株式会社大分大学先端医学研究所 |
用于治疗狂犬病的环状酰胺化合物及其方法
|
AU2020344675A1
(en)
|
2019-09-13 |
2022-03-31 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
CA3157798A1
(fr)
|
2019-11-12 |
2021-05-20 |
Zhongli Gao |
Heteroarylaminosulfonamides a 6 chainons pour le traitement de maladies et d'etats medies par une activite cftr deficiente
|
WO2021113809A1
(fr)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides et leurs procédés d'utilisation
|
WO2021113806A1
(fr)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides et leurs procédés d'utilisation
|
CN114901290A
(zh)
|
2019-12-16 |
2022-08-12 |
蔚山科学技术院 |
抑制血管新生因子的化合物及其用途
|
WO2021158959A2
(fr)
|
2020-02-07 |
2021-08-12 |
Elektrofi, Inc. |
Particules peptidiques et procédés de formation
|
WO2021168271A1
(fr)
|
2020-02-19 |
2021-08-26 |
Elektrofi, Inc. |
Formation de gouttelettes et morphologie de particules
|
CN115484934A
(zh)
|
2020-04-17 |
2022-12-16 |
伊勒卓菲公司 |
通过连续液滴形成和脱水形成颗粒的方法
|
WO2021263072A1
(fr)
|
2020-06-25 |
2021-12-30 |
Dana-Farber Cancer Institute, Inc. |
Méthodes de traitement d'une maladie
|
CN111830151B
(zh)
*
|
2020-07-01 |
2021-05-04 |
迪沙药业集团有限公司 |
盐酸安非他酮组合物质量控制用系统适用性对照品
|
CA3191164A1
(fr)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
1,2,4-oxadiazoles substitues utilises en tant qu'inhibiteurs de petites molecules de la protease 28 specifique de l'ubiquitine
|
CA3191163A1
(fr)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs a petites molecules pyrimidine-thieno-pyridine tricycliques fusionnees de la protease 28 specifique de l'ubiquitine
|
US20230271918A1
(en)
|
2020-08-10 |
2023-08-31 |
Dana-Farber Cancer Institute, Inc. |
Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
|
EP4232161A1
(fr)
|
2020-10-23 |
2023-08-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs covalents de créatine kinase (ck) et leurs utilisations dans le traitement et la prévention du cancer
|
WO2022133237A2
(fr)
|
2020-12-18 |
2022-06-23 |
Cornell University |
Méthodes de traitement de troubles neurodégénératifs et de cancers liés à stat3 au moyen de suppresseurs de fuite d'électrons
|
IL303813A
(en)
|
2020-12-21 |
2023-08-01 |
Univ Cornell |
A peptide-linked drug delivery system
|
WO2022150574A1
(fr)
|
2021-01-08 |
2022-07-14 |
Cornell University |
Inhibiteurs de la lipoamide déshydrogénase de mycobacterium tuberculosis
|
EP4323356A1
(fr)
|
2021-04-13 |
2024-02-21 |
Nuvalent, Inc. |
Hétérocycles amino-substitués pour le traitement de cancers avec des mutations egfr
|
EP4396176A1
(fr)
|
2021-09-03 |
2024-07-10 |
Genzyme Corporation |
Composés indoles et leurs utilisations dans le traitement de la fibrose kystique
|
KR20240076791A
(ko)
|
2021-09-03 |
2024-05-30 |
젠자임 코포레이션 |
인돌 화합물 및 사용 방법
|
IL311444A
(en)
|
2021-10-01 |
2024-05-01 |
Nuvalent Inc |
Solid forms, pharmaceutical preparations and preparation of macrocyclic heteroaromatic ether compounds
|
KR20240095536A
(ko)
|
2021-10-01 |
2024-06-25 |
뉴베일런트, 아이엔씨. |
헤테로방향족 매크로사이클릭 에테르 화합물을 사용한 고형 종양의 치료 방법
|
WO2023187422A1
(fr)
|
2022-03-31 |
2023-10-05 |
Revolo Biotherapeutics Limited |
Compositions et leur utilisation dans des procédés pour traiter une inflammation intestinale
|
WO2023196910A1
(fr)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc |
Méthodes de traitement d'une tumeur solide à l'aide de (19r)-5-chloro-3-éthyl-16-fluoro-10,19-diméthyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6. 08,12.013,18]pentacosa-1(24), 2(6),4,8,11,13,15,17,21(25),22-décaén-22-amine
|
TW202400608A
(zh)
|
2022-04-07 |
2024-01-01 |
美商努法倫特公司 |
雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
|
WO2023212721A1
(fr)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Suspensions injectables
|
WO2023223015A1
(fr)
|
2022-05-16 |
2023-11-23 |
Revolo Biotherapeutics Limited |
Méthodes et compositions de prévention ou de traitement d'allergies alimentaires
|
WO2023250157A1
(fr)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibiteurs de mycobacterium tuberculosis lipoamide déshydrogénase
|
WO2024013209A1
(fr)
|
2022-07-13 |
2024-01-18 |
Astrazeneca Ab |
Inhibiteurs de pcsk9 et leurs procédés d'utilisation
|
WO2024036098A1
(fr)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Composés d'éther macrocycliques hétéroaromatiques
|
WO2024036097A1
(fr)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Composés d'éther macrocycliques hétéroaromatiques et isotopologues de ceux-ci
|
WO2024073334A1
(fr)
|
2022-09-26 |
2024-04-04 |
Rose Research Center, Llc |
Combinaison destinée à être utilisée dans un procédé de prévention de gain de poids
|
WO2024086634A1
(fr)
|
2022-10-19 |
2024-04-25 |
Nuvalent, Inc. |
Agents chimiothérapeutiques à base d'éther macrocyclique hétéroaromatique
|